BR112019012570A8 - Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo - Google Patents
Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpoInfo
- Publication number
- BR112019012570A8 BR112019012570A8 BR112019012570A BR112019012570A BR112019012570A8 BR 112019012570 A8 BR112019012570 A8 BR 112019012570A8 BR 112019012570 A BR112019012570 A BR 112019012570A BR 112019012570 A BR112019012570 A BR 112019012570A BR 112019012570 A8 BR112019012570 A8 BR 112019012570A8
- Authority
- BR
- Brazil
- Prior art keywords
- complex
- polynucleotide
- antibody
- vector
- detection
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- 238000001514 detection method Methods 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5443—IL-15
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437143P | 2016-12-21 | 2016-12-21 | |
| PCT/US2017/067917 WO2018119246A1 (en) | 2016-12-21 | 2017-12-21 | Antibodies that specifically bind to human il-15 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112019012570A2 BR112019012570A2 (pt) | 2019-11-26 |
| BR112019012570A8 true BR112019012570A8 (pt) | 2023-01-24 |
Family
ID=62627610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019012570A BR112019012570A8 (pt) | 2016-12-21 | 2017-12-21 | Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11267883B2 (enExample) |
| EP (2) | EP3558369B1 (enExample) |
| JP (2) | JP7155126B2 (enExample) |
| KR (2) | KR102706743B1 (enExample) |
| CN (1) | CN110234349B (enExample) |
| AR (1) | AR110414A1 (enExample) |
| AU (2) | AU2017382850B2 (enExample) |
| BR (1) | BR112019012570A8 (enExample) |
| CA (1) | CA3046387A1 (enExample) |
| CL (1) | CL2019001729A1 (enExample) |
| DK (1) | DK3558369T3 (enExample) |
| EA (1) | EA201991514A1 (enExample) |
| ES (1) | ES3026508T3 (enExample) |
| FI (1) | FI3558369T3 (enExample) |
| HR (1) | HRP20250482T1 (enExample) |
| HU (1) | HUE071878T2 (enExample) |
| IL (1) | IL267113B2 (enExample) |
| LT (1) | LT3558369T (enExample) |
| MA (1) | MA47130B1 (enExample) |
| MD (1) | MD3558369T2 (enExample) |
| MX (2) | MX2019007357A (enExample) |
| PE (1) | PE20191497A1 (enExample) |
| PH (1) | PH12019501453A1 (enExample) |
| PL (1) | PL3558369T3 (enExample) |
| PT (1) | PT3558369T (enExample) |
| RS (1) | RS66900B1 (enExample) |
| SI (1) | SI3558369T1 (enExample) |
| UA (1) | UA126284C2 (enExample) |
| WO (1) | WO2018119246A1 (enExample) |
| ZA (1) | ZA201903848B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3030682B1 (en) | 2013-08-05 | 2020-06-03 | Twist Bioscience Corporation | De novo synthesized gene libraries |
| CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| JP6982362B2 (ja) | 2015-09-18 | 2021-12-17 | ツイスト バイオサイエンス コーポレーション | オリゴ核酸変異体ライブラリーとその合成 |
| KR20250053972A (ko) | 2015-09-22 | 2025-04-22 | 트위스트 바이오사이언스 코포레이션 | 핵산 합성을 위한 가요성 기판 |
| WO2018057526A2 (en) | 2016-09-21 | 2018-03-29 | Twist Bioscience Corporation | Nucleic acid based data storage |
| PT3558369T (pt) | 2016-12-21 | 2025-05-06 | Cephalon Llc | Anticorpos que se ligam especificamente à il-15 humana e suas utilizações |
| WO2018156792A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| SG11201912057RA (en) | 2017-06-12 | 2020-01-30 | Twist Bioscience Corp | Methods for seamless nucleic acid assembly |
| JP2020536504A (ja) | 2017-09-11 | 2020-12-17 | ツイスト バイオサイエンス コーポレーション | Ｇｐｃｒ結合タンパク質およびその合成 |
| GB2583590A (en) | 2017-10-20 | 2020-11-04 | Twist Bioscience Corp | Heated nanowells for polynucleotide synthesis |
| GB2585506A (en) | 2018-01-04 | 2021-01-13 | Twist Bioscience Corp | DNA-based digital information storage |
| CN118957038A (zh) | 2018-05-18 | 2024-11-15 | 特韦斯特生物科学公司 | 用于核酸杂交的多核苷酸、试剂和方法 |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| WO2020138073A1 (ja) | 2018-12-25 | 2020-07-02 | Ntn株式会社 | 流量制御バルブ用シールおよび流量制御バルブ装置 |
| CN113692409B (zh) | 2018-12-26 | 2025-01-10 | 特韦斯特生物科学公司 | 高度准确的从头多核苷酸合成 |
| JP2022522668A (ja) | 2019-02-26 | 2022-04-20 | ツイスト バイオサイエンス コーポレーション | 抗体を最適化するための変異体核酸ライブラリ |
| AU2020229349A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for GLP1 receptor |
| AU2020291012B2 (en) | 2019-06-12 | 2025-09-25 | AskGene Pharma, Inc. | Novel IL-15 prodrugs and methods of use thereof |
| EP3987019A4 (en) | 2019-06-21 | 2023-04-19 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| CN115023440B (zh) | 2019-09-23 | 2025-09-12 | 特韦斯特生物科学公司 | 结合CD3ε的抗体 |
| EP4034566A4 (en) | 2019-09-23 | 2024-01-24 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CRTH2 |
| BR112022011235A2 (pt) * | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| JP2023545821A (ja) * | 2020-10-16 | 2023-10-31 | ジェネンテック， インコーポレイテッド | 抗ｉＣａｓｐａｓｅ切断基質抗体および使用方法 |
| EP4281112A4 (en) | 2021-01-21 | 2025-01-15 | Twist Bioscience Corporation | METHODS AND COMPOSITIONS RELATING TO ADENOSINE RECEPTORS |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| JP2025525860A (ja) | 2022-08-04 | 2025-08-07 | ノバルティス ファーマ アーゲー | アトピー性皮膚炎の治療に有用なｉｌ－１５阻害剤 |
| CN118894934A (zh) * | 2023-05-05 | 2024-11-05 | 北京智仁美博生物科技有限公司 | 抗人il-15的抗体及其用途 |
| CN117209605B (zh) * | 2023-11-09 | 2024-01-30 | 北京百普赛斯生物科技股份有限公司 | 特异性结合il-15的抗体及其应用 |
| WO2025227052A1 (en) * | 2024-04-26 | 2025-10-30 | Cephalon Llc | Doses and formulations of anti-il-15 antibody for the treatment of immune diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US7132510B2 (en) * | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
| US7329405B2 (en) * | 2001-08-23 | 2008-02-12 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
| US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| EP1425389B1 (en) * | 2001-08-23 | 2011-11-02 | Genmab A/S | Human antibodies specific for interleukin 15 (il-15) |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| ZA200506724B (en) * | 2003-02-26 | 2007-03-28 | Genmab As | Human antibodies specific for interleukin 15 (IL-15) |
| WO2006020849A2 (en) * | 2004-08-11 | 2006-02-23 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15 polypeptides |
| AU2006216291B2 (en) | 2005-02-27 | 2011-01-27 | Institute For Antibodies Co., Ltd. | Anti-IgSF4 antibody and utilization of the same |
| EP2439273B1 (en) * | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP2336329B8 (en) | 2007-06-01 | 2012-11-21 | Omt, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| EP2564695B1 (en) * | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
| UY32949A (es) * | 2009-10-15 | 2011-02-28 | Abbott Lab | Proteínas de unión a il-1 |
| EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| EP2596022A4 (en) * | 2010-07-20 | 2014-11-05 | Cephalon Australia Pty Ltd | SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23 |
| JP5820688B2 (ja) | 2011-03-23 | 2015-11-24 | 株式会社Kri | 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法 |
| KR20140048292A (ko) | 2011-08-23 | 2014-04-23 | 로슈 글리카트 아게 | 항-mcsp 항체 |
| EA034989B1 (ru) * | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| EP3444278A1 (en) * | 2013-02-26 | 2019-02-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP2963057A1 (en) | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| SMT202100086T1 (it) * | 2015-03-31 | 2021-03-15 | Medimmune Ltd | Una nuova forma di il33, forme mutate di il33, anticorpi, saggi e metodi per usare gli stessi |
| CN109311972A (zh) * | 2016-06-15 | 2019-02-05 | 美国安进公司 | 用于治疗乳糜泻、非乳糜泻麸质敏感和难治性乳糜泻的方法和组合物 |
| MA46534A (fr) | 2016-10-14 | 2019-08-21 | Xencor Inc | Protéines de fusion fc hétérodimères il15/il15r |
| PT3558369T (pt) | 2016-12-21 | 2025-05-06 | Cephalon Llc | Anticorpos que se ligam especificamente à il-15 humana e suas utilizações |
-
2017
- 2017-12-21 PT PT178838009T patent/PT3558369T/pt unknown
- 2017-12-21 SI SI201731602T patent/SI3558369T1/sl unknown
- 2017-12-21 UA UAA201908753A patent/UA126284C2/uk unknown
- 2017-12-21 HR HRP20250482TT patent/HRP20250482T1/hr unknown
- 2017-12-21 FI FIEP17883800.9T patent/FI3558369T3/fi active
- 2017-12-21 IL IL267113A patent/IL267113B2/en unknown
- 2017-12-21 RS RS20250577A patent/RS66900B1/sr unknown
- 2017-12-21 MD MDE20191253T patent/MD3558369T2/ro unknown
- 2017-12-21 DK DK17883800.9T patent/DK3558369T3/da active
- 2017-12-21 EA EA201991514A patent/EA201991514A1/ru unknown
- 2017-12-21 MX MX2019007357A patent/MX2019007357A/es unknown
- 2017-12-21 MA MA47130A patent/MA47130B1/fr unknown
- 2017-12-21 CA CA3046387A patent/CA3046387A1/en active Pending
- 2017-12-21 US US16/471,616 patent/US11267883B2/en active Active
- 2017-12-21 EP EP17883800.9A patent/EP3558369B1/en active Active
- 2017-12-21 KR KR1020237031493A patent/KR102706743B1/ko active Active
- 2017-12-21 PL PL17883800.9T patent/PL3558369T3/pl unknown
- 2017-12-21 EP EP25165676.5A patent/EP4585261A3/en active Pending
- 2017-12-21 PE PE2019001283A patent/PE20191497A1/es unknown
- 2017-12-21 ES ES17883800T patent/ES3026508T3/es active Active
- 2017-12-21 BR BR112019012570A patent/BR112019012570A8/pt unknown
- 2017-12-21 CN CN201780079926.6A patent/CN110234349B/zh active Active
- 2017-12-21 AR ARP170103614A patent/AR110414A1/es unknown
- 2017-12-21 LT LTEPPCT/US2017/067917T patent/LT3558369T/lt unknown
- 2017-12-21 HU HUE17883800A patent/HUE071878T2/hu unknown
- 2017-12-21 WO PCT/US2017/067917 patent/WO2018119246A1/en not_active Ceased
- 2017-12-21 KR KR1020197019269A patent/KR20190097094A/ko not_active Abandoned
- 2017-12-21 AU AU2017382850A patent/AU2017382850B2/en active Active
- 2017-12-21 JP JP2019533652A patent/JP7155126B2/ja active Active
-
2019
- 2019-06-13 ZA ZA2019/03848A patent/ZA201903848B/en unknown
- 2019-06-19 MX MX2023014081A patent/MX2023014081A/es unknown
- 2019-06-20 CL CL2019001729A patent/CL2019001729A1/es unknown
- 2019-06-21 PH PH12019501453A patent/PH12019501453A1/en unknown
-
2022
- 2022-01-05 US US17/647,082 patent/US12410247B2/en active Active
- 2022-10-05 JP JP2022161059A patent/JP2022176324A/ja active Pending
-
2025
- 2025-02-20 AU AU2025201185A patent/AU2025201185A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019012570A8 (pt) | Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo | |
| MX2024011328A (es) | Proteinas de union gfral y uso de las mismas | |
| CO2019006485A2 (es) | Anticuerpos y metodos de su utilizacion | |
| BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
| AR103726A1 (es) | Cristales de anticuerpos monoclonales anti-pd-1 humanos | |
| UY37928A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| MX387562B (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| MX2022015823A (es) | Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos. | |
| BR112017020054A2 (pt) | anticorpos para icos | |
| MX2016006709A (es) | Moduladores de aplnr y usos de estos. | |
| BR112018015480A2 (pt) | proteínas de ligação ao antígeno que se ligam a pd-l1 | |
| BR112016010513A2 (pt) | anticorpos anti-il-17, método de produção e uso dos mesmos | |
| UY36289A (es) | ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN | |
| GEP20227419B (en) | Pd-1-binding molecules and methods of use thereof | |
| MX2016009555A (es) | Proteinas de union y metodos para utilizarlas. | |
| EA201890337A1 (ru) | Конструкции антитела к flt3 и cd3 | |
| BR112016002199B8 (pt) | Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma | |
| MX377772B (es) | Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos. | |
| BR112019027133A2 (pt) | células imunes deficientes para suv39h1 | |
| BR112019000621A2 (pt) | anticorpos tgfss, métodos e usos | |
| BR112016021066A2 (pt) | anticorpos humanizados com estabilidade aumentada | |
| MX2016005762A (es) | Region variable de anticuerpo modificada que contiene molecula de union al antigeno. | |
| BR112016025056A2 (pt) | uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica | |
| CL2020001726A1 (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: CEPHALON LLC (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: CEPHALON LLC (US) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024020794-0 PROTOCOLO 870240085774 EM 07/10/2024 15:11. |